ECMO News…News reports and updates related to ECMO from around the globe.


Getting Rid of Heparin

Bioinspired coating for medical devices repels blood and bacteria

The negative effects of heparin is one of the greatest dangers ECMO patients face. There is a constant effort underway to discover safe and efficient ways to circulate blood through the extracorporeal circuit without the use of heparin. The work by this group out of Boston looks promising!

Emerging Technology in the Extracorporeal World

Monday February 2, 2015

MONMOUTH JUNCTION, N.J., Feb. 2, 2015 – CytoSorbents Corporation (NASDAQ CM: CTSO), a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to treat critically-ill and cardiac surgery patients in multiple countries worldwide, announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application to commence a planned U.S. cardiac surgery feasibility study. This single-arm study in 20 patients and three U.S. clinical sites represents the first part of a larger clinical trial strategy intended to support the U.S. approval of CytoSorb® for intra-operative use during cardiac surgery.

The goal of CytoSorb® is to modulate the immune system by removing excessive cytokines, often called “cytokine storm”, and other inflammatory toxins in critically-ill patients that can lead to deadly inflammation, multiple organ failure, immune dysfunction, and often death. CytoSorb® therapy has been associated with statistically significant reductions in mortality in septic patients at high risk of death in a small study.

Read more about it!

Medos and NovaLung

JANUARY 9, 2014
NovaLung receives 510k Clearance to market Medos Hilite 7000 & 7000 LT Oxygenator

Xenios Pediatrics – Innovations for Pediatric Care

Because kids will be kids
After founding Xenios AG earlier this year, Novalung GmbH and Medos Medizintechnik AG have now jointly started the Xenios Pediatrics business unit.
Xenios Pediatrics combines the leading extracorporeal systems from Medos and Novalung and thus creates a unique ECMO offering for pediatric intensive care. Neonates, babies and children with severe pulmonary or cardiac failure can be treated using extracorporeal membrane oxygenation (ECMO). With the help of this extracorporeal organ replacement procedure sufficient oxygenation can be maintained for days or weeks.Based on years of experience in the field, Novalung and Medos have recognized the need for advanced extracorporeal therapy systems in pediatric and neonatal care. The next step is the decision to develop new system solutions together with the established pediatric ECMO centers.Xenios Pediatrics focusses exclusively on the pediatric and neonatal field and offers a unique portfolio of products for patient-specific solutions for the entire spectrum of extracorporeal cardiopulmonary support. Xenios Pediatrics will continue to pursue a close working relationship with doctors and nurses to launch an innovation initiative for pediatric ECMO.

Media Contact: 

Hilda Bielz
Xenios AG

Telefon +49 7131 2706 422
Telefax +49 7131 2706 299

Xenios AG
Im Zukunftspark 1
74076 Heilbronn, Germany